Abstract
A dismal investment climate for publicly traded biotech companies is causing startups and their backers to tighten their belts, investors and analysts say. Biotechnology industry watchers were hopeful at the start of 2025. Venture funding appeared to be rebounding after a lengthy slump, and a smattering of new stock offerings and company acquisitions brewed optimism that the public markets might be similarly warming up to young drugmakers.
Key Data
-
Publication Date20 June 2025
-
Primary AuthorGwendolyn Wu
-
SourceBioPharma Dive
-
LanguageEnglish
Click below to visit original source: